Document is current
Any future updates will be listed below
-
Authors
Hatano, Mai
Nakajima, Waki
Tsuchimoto, Shohei
Arisawa, Tetsu
Takada, Yuuki
Eiro, Tsuyoshi
Abe, Hiroki
Ichijo, Sadamitsu
Fujimoto, Yu
Sano, Akane
Syed, Shariful A.
Tani, Hideaki
Nagai, Nobuhiro
Koizumi, Teruki
Nakajima, Shinichiro
Nomoto-Takahashi, Kie
Ohtani, Yohei
Jinzaki, Masahiro
Hirano, Yoji
Mitoma, Ryo
Tamura, Shunsuke
Baba, Shingo
Togao, Osamu
Kosaka, Hirotaka
Okazawa, Hidehiko
Kimura, Yuichi
Mimura, Masaru
Uchida, Hiroyuki
Takahashi, Takuya https://orcid.org/0000-0001-6523-0622
-
Funding
Funding for this research was provided by:
Ministry of Education, Culture, Sports, Science and Technology
Japan Agency for Medical Research and Development (JP18dm0207023)
Japan Agency for Medical Research and Development (JP20dm0107124)
Japan Agency for Medical Research and Development (JP24wm0625302)
Japan Agency for Medical Research and Development (JP22dm0207072)
Japan Agency for Medical Research and Development (JP24wm0625304)
Japan Agency for Medical Research and Development (JP25gm7010019)
Takeda Science Foundation
Japan Society for the Promotion of Science (20H00549)
Japan Society for the Promotion of Science (20H05922)
Japan Society for the Promotion of Science (19H03587)
Japan Society for the Promotion of Science (20K20603)
Japan Society for the Promotion of Science (22H03001)
Japan Society for the Promotion of Science (22K15793)
Japan Society for the Promotion of Science (20KK0193)
Japan Society for the Promotion of Science (21H02851)
Japan Society for the Promotion of Science (25K19145)
Japan Society for the Promotion of Science (23K10432)
Keio Next-Generation Research Project Program
SENSHIN Medical Research Foundation
Japan Research Foundation for Clinical Pharmacology
- License Information
-
More Information
Article History
Received: 5 February 2026
Accepted: 25 May 2026
First Online: 22 June 2026
Declarations
:
: This research consisted of four clinical studies registered under the following IDs: UMIN000020975, UMIN000025132, jRCTs031200083, and jRCTs031210312. The Yokohama City University Human Investigation Committee and the Certified Institutional Review Board approved each study. The Ethical Guidelines for Medical and Health Research Involving Human Participants set by the Japan Ministry of Health, Labour and Welfare, as well as the Clinical Trials Act in Japan, were adhered to in each study.
: Informed consent was obtained from all individual participants included in the study.
: All participants provided written informed consent for the publication of anonymized images and relevant data included in this article.
: Takuya Takahashi is the inventors of a patent application for a novel compound that specifically binds to the AMPA receptor (WO 2017006931), including [ 11 C]K-2. Takuya Takahashi and Tetsu Arisawa are the founders and also stockholders of AMPAMETRY, Inc., which holds the exclusive license to use [ 11 C]K-2. No other potential conflicts of interest relevant to this article exist.
